Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for (Study ST000677)

(Analysis AN001040)

Metabolite	Structure	F1	F2	F3	F4	F5	F6
CL 66:1; [M-2H](2-)@6.29	ME187792	0.88	2.31	0.68	1.06	0.94	0.43
PE 32:1; [M-H]-@6.31	ME187846	0.88	1.96	0.70	1.06	1.06	0.53
plasmenyl-PE 36:5; [M-H]-@6.36	ME187901	0.58	0.68	0.76	1.31	0.72	1.47
lysoPE 20:5; [M-H]-@1.13	ME187889	0.64	0.38	0.88	1.08	1.12	1.66
lysoPE 22:6; [M-H]-@1.34	ME187892	0.81	0.58	0.97	0.98	1.07	1.53
PE 32:0; [M-H]-@6.81	ME187845	0.97	0.63	0.61	1.13	1.65	0.59
PE 36:0; [M-H]-@7.95	ME187851	1.16	0.86	0.82	0.90	1.31	0.92
lysoPE 20:3; [M-H]-@1.68	ME187887	0.76	0.76	0.95	0.99	1.46	1.08
PC 40:2; [M-Ac-H]-@8.28	ME187839	0.77	0.74	1.00	1.19	1.39	0.64
lysoPE 22:4; [M-H]-@1.99	ME187890	1.26	1.16	0.65	0.78	1.00	1.30
PC 42:10; [M-Ac-H]-@5.85	ME187844	1.10	1.08	0.57	0.99	0.99	1.12
PC 37:3; [M-Ac-H]-@6.86	ME187831	0.91	0.93	0.79	1.29	0.91	0.73
FFA(20:1)	ME187801	1.38	1.00	0.84	0.89	0.87	0.97
FFA(20:2)	ME187802	1.31	1.02	0.89	0.90	0.90	0.98
FFA(18:1)	ME187798	1.25	1.15	0.93	0.91	0.89	0.95
FFA(18:2)	ME187799	1.20	1.12	0.89	0.90	0.86	1.10
FFA(20:4) Arachidonic acid	ME187803	1.27	1.04	0.78	0.93	0.77	1.15
PI 36:4; [M-H]-@5.26	ME187875	1.37	1.05	0.65	0.98	0.74	1.01
PC 40:4; [M-Ac-H]-@7.45	ME187840	1.26	0.85	0.72	1.01	0.87	1.04
PI 38:4; [M-H]-@5.88	ME187878	1.38	0.90	0.67	1.07	0.61	1.00
PC 38:4; [M-Ac-H]-@6.89	ME187836	1.27	0.75	0.76	1.07	0.72	1.07
FFA(24:3)	ME187810	1.31	0.86	0.83	1.04	0.64	1.06
PI 38:3; [M-H]-@6.10	ME187877	1.36	0.92	0.81	0.98	0.73	1.03
N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.96	ME187813	0.97	0.74	1.13	1.06	1.00	0.98
N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.52	ME187811	1.08	0.91	1.13	1.05	0.81	0.92
PC 35:2; [M-Ac-H]-@6.70	ME187825	1.06	0.82	1.14	1.04	0.92	0.92
FFA(22:2)	ME187805	1.23	0.84	0.94	1.02	0.87	0.93
PC 40:7; [M-Ac-H]-@6.36	ME187843	1.04	0.69	0.92	1.09	1.01	0.99
FFA(22:3)	ME187806	1.06	0.88	0.92	1.01	1.01	1.02
PE 40:5; [M-H]-@7.25	ME187865	0.97	0.84	0.90	1.11	1.04	0.94
plasmenyl-PE 36:3; [M-H]-@7.00	ME187899	0.95	1.19	0.85	1.14	0.67	1.03
plasmenyl-PE 34:1; [M-H]-@7.27	ME187894	0.92	1.07	0.92	1.09	0.75	1.16
plasmenyl-PE 34:2; [M-H]-@6.78	ME187895	0.93	1.15	0.92	1.10	0.73	1.08
plasmenyl-PE 36:2; [M-H]-@7.36	ME187898	0.96	1.08	0.89	1.12	0.71	1.07
plasmenyl-PE 36:4; [M-H]-@6.73	ME187900	1.06	1.14	0.70	1.08	0.60	1.25
plasmenyl-PE 38:4; [M-H]-@7.31	ME187904	1.03	1.10	0.83	1.04	0.66	1.24
plasmenyl-PE 38:5; [M-H]-@6.83	ME187905	0.99	1.14	0.81	1.10	0.66	1.16
PE 38:5; [M-H]-@6.57	ME187862	0.98	0.90	0.93	1.14	0.76	1.06
PE 40:6; [M-H]-@6.97	ME187866	0.97	0.89	0.87	1.17	0.79	1.01
PE 40:4; [M-H]-@7.50	ME187864	1.07	0.90	0.85	1.09	0.84	1.01
PG 36:2; [M-H]-@6.08	ME187870	1.07	0.92	0.84	1.11	0.82	0.98
PC 32:0; [M-Ac-H]-@6.77	ME187818	1.02	1.01	0.89	1.07	0.83	1.05
FFA(24:2)	ME187809	1.06	1.00	0.81	1.06	0.80	1.10
plasmenyl-PE 40:6; [M-H]-@7.27	ME187909	1.05	0.99	0.84	1.08	0.78	1.09
plasmenyl-PE 40:3; [M-H]-@8.13	ME187907	1.13	0.92	0.85	1.08	0.70	1.10
plasmenyl-PE 40:5; [M-H]-@7.35	ME187908	1.00	0.91	0.74	1.14	0.79	1.13
plasmenyl-PE 36:1; [M-H]-@7.82	ME187897	1.02	1.00	0.84	1.09	0.68	1.19
plasmenyl-PE 38:6; [M-H]-@6.62	ME187906	1.02	0.93	0.83	1.07	0.77	1.21
lysoPE 16:0; [M-H]-@1.69	ME187883	0.99	1.05	0.99	1.03	0.79	1.14
lysoPE 18:0; [M-H]-@2.49	ME187884	1.04	1.01	0.91	1.01	0.81	1.18
FFA(24:0)	ME187807	0.86	0.90	1.08	1.12	0.80	1.13
PE 40:8; [M-H]-@6.04	ME187868	0.93	0.96	0.94	1.11	0.73	1.19
plasmenyl-PE 38:3; [M-H]-@7.62	ME187903	0.96	0.89	0.99	1.07	0.80	1.16
PI 40:5; [M-H]-@5.99	ME187881	1.20	1.05	0.78	1.04	0.78	0.98
PE 38:2; [M-H]-@6.95	ME187859	1.15	1.12	0.93	1.07	0.67	0.93
PE 38:4; [M-H]-@7.02	ME187861	1.12	0.98	0.92	1.10	0.76	0.91
PC 33:2; [M-Ac-H]-@6.11	ME187822	0.93	1.08	1.12	1.05	0.78	1.06
PC 34:3; [M-Ac-H]-@5.93	ME187823	1.00	1.00	1.02	1.07	0.86	0.96
FFA(20:0)	ME187800	0.93	1.11	1.06	1.05	0.85	1.01
PC 36:3; [M-Ac-H]-@6.54	ME187828	1.01	1.10	1.03	1.04	0.84	0.97
PC 36:1; [M-Ac-H]-@7.50	ME187827	0.94	1.07	0.88	1.05	0.93	1.07
PI 37:4; [M-H]-@5.59	ME187876	1.00	1.02	1.02	0.99	1.00	1.01
PE 37:4; [M-H]-@6.72	ME187857	1.06	1.05	0.87	1.04	0.99	0.87
PC 38:3; [M-Ac-H]-@7.26	ME187835	1.03	1.13	0.87	1.03	0.92	0.97
PC 37:4; [M-Ac-H]-@6.68	ME187832	1.04	1.17	0.83	1.08	0.94	0.82
PE 36:4; [M-H]-@6.28	ME187855	1.05	1.14	0.92	1.08	0.85	0.86
plasmenyl-PE 38:2; [M-H]-@7.97	ME187902	1.07	1.15	0.87	1.06	0.90	0.86
FFA(16:0)	ME187796	1.06	1.26	0.97	0.97	0.86	0.96
FFA(18:0)	ME187797	1.03	1.24	1.00	0.99	0.87	0.95
PC 30:0; [M-Ac-H]-@6.11	ME187816	1.01	1.24	0.93	1.10	0.78	0.86
PI 36:2; [M-H]-@5.92	ME187874	1.11	1.30	0.87	1.03	0.77	0.90
lysoPE 22:5; [M-H]-@1.58	ME187891	1.09	0.81	1.01	0.85	0.98	1.38
lysoPE 18:2; [M-H]-@1.40	ME187886	0.77	0.98	1.04	1.03	0.98	1.23
lysoPE 18:1; [M-H]-@1.86	ME187885	0.83	0.92	1.18	0.96	0.87	1.37
PE 38:1; [M-H]-@7.53	ME187858	0.96	0.76	1.22	0.95	0.86	1.32
PE 36:5; [M-H]-@6.02	ME187856	0.73	0.95	0.67	1.24	0.93	1.13
PC 40:6; [M-Ac-H]-@6.81	ME187842	0.98	0.71	0.95	1.06	0.94	1.17
lysoPE 20:4; [M-H]-@1.37	ME187888	1.07	0.76	0.86	1.01	0.89	1.25
PC 38:5; [M-Ac-H]-@6.52	ME187837	1.09	0.73	0.89	1.06	0.84	1.15
PC 36:5; [M-Ac-H]-@5.84	ME187829	0.89	0.67	0.80	1.13	0.91	1.29
PI 38:5; [M-H]-@5.40	ME187879	0.91	0.79	0.77	1.09	0.98	1.21
PI 40:6; [M-H]-@5.83	ME187882	0.99	0.93	0.73	0.98	0.99	1.29
plasmenyl-PE 42:5; [M-H]-@7.95	ME187910	0.94	0.91	0.62	1.09	0.80	1.39
CL 74:3; [M-2H](2-)@7.01	ME187794	0.79	1.65	1.28	1.04	0.78	0.79
PC 28:0; [M-Ac-H]-@5.41	ME187815	0.93	1.42	1.29	0.99	0.83	0.81
PC 38:2; [M-Ac-H]-@7.64	ME187834	1.14	1.44	0.80	0.97	0.86	0.85
PI 34:2; [M-H]-@5.26	ME187873	1.10	1.65	0.62	1.01	0.81	0.85
PC 35:3; [M-Ac-H]-@6.26	ME187826	0.72	1.38	0.91	1.11	0.76	1.15
PI 38:6; [M-H]-@5.14	ME187880	0.86	1.32	0.82	0.96	0.94	1.25
PE 38:3; [M-H]-@7.31	ME187860	0.92	1.44	0.98	1.09	1.03	0.59
CerP 34:1; [M-H]-@5.96	ME187795	0.99	1.42	0.82	1.03	1.03	0.74
PC 30:1; [M-Ac-H]-@5.55	ME187817	0.98	1.25	0.92	1.07	0.99	0.76
PE 35:2; [M-H]-@6.76	ME187850	0.88	1.17	1.18	1.10	1.00	0.69
CL 70:5; [M-2H](2-)@6.00	ME187793	0.81	1.51	0.99	1.11	0.75	0.91
PE 36:2; [M-H]-@7.07	ME187853	0.79	1.28	1.16	1.12	0.88	0.84
PE 36:3; [M-H]-@6.62	ME187854	0.81	1.29	1.11	1.11	0.85	0.88
PE 34:1; [M-H]-@6.94	ME187847	0.86	1.30	0.95	1.12	0.90	0.85
PE 34:3; [M-H]-@6.05	ME187849	0.84	1.27	0.88	1.15	0.84	0.91
PC 32:1; [M-Ac-H]-@6.25	ME187819	0.93	1.49	0.69	1.01	1.05	0.91
PI 34:1; [M-H]-@5.71	ME187872	0.91	1.31	0.61	1.08	1.22	0.76
PC 37:2; [M-Ac-H]-@7.38	ME187830	0.97	1.35	1.05	0.87	1.05	1.03
PC 33:1; [M-Ac-H]-@6.59	ME187821	0.92	1.23	0.85	1.00	1.04	1.00
PG 38:4; [M-H]-@6.07	ME187871	0.88	1.26	0.83	1.01	1.19	0.88
PE 36:1; [M-H]-@7.53	ME187852	0.81	1.09	1.27	1.07	0.83	1.03
PE 40:7; [M-H]-@6.47	ME187867	0.86	0.80	1.25	1.13	0.81	1.04
plasmenyl-PE 32:1; [M-H]-@6.67	ME187893	0.78	0.89	1.23	1.15	0.96	0.89
PC 32:2; [M-Ac-H]-@5.74	ME187820	0.93	0.90	1.47	1.05	0.94	0.81
PE 34:2; [M-H]-@6.48	ME187848	0.70	0.94	1.35	1.17	1.09	0.73
FFA(22:0)	ME187804	0.74	0.67	1.26	1.09	1.02	1.15
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.89	ME187812	0.79	0.69	1.18	1.08	1.08	1.10
FFA(24:1)	ME187808	0.88	0.63	1.06	1.09	1.07	1.08
PC 38:7; [M-Ac-H]-@5.65	ME187838	0.86	0.61	1.07	1.05	1.20	1.09
PC 40:5; [M-Ac-H]-@7.22	ME187841	0.88	0.62	1.11	1.00	1.26	1.08
PE 38:6; [M-H]-@6.20	ME187863	0.77	0.58	1.36	1.22	0.87	0.96
PA 34:2; [M-H]-@6.38	ME187814	0.91	0.70	1.44	0.92	1.12	1.08
PC 34:4; [M-Ac-H]-@5.62	ME187824	0.89	0.51	1.51	1.09	1.05	0.88
PC 37:6; [M-Ac-H]-@5.92	ME187833	0.75	0.50	1.50	1.06	1.10	1.10
PG 33:0; [M-H]-@6.10	ME187869	1.06	0.85	1.54	0.97	0.62	1.11
plasmenyl-PE 34:3; [M-H]-@6.42	ME187896	0.68	0.63	1.68	1.22	0.68	1.04

Factors:

F1	visit:closeout
F2	visit:initial visit
F3	visit:intitial visit
F4	visit:month 1
F5	visit:month 12
F6	visit:visit 1

Data matrix